| Literature DB >> 29252214 |
Hana Janova1,2, Sahab Arinrad1, Evan Balmuth1, Marina Mitjans1,2, Johannes Hertel3, Mohamad Habes3,4, Robert A Bittner5, Hong Pan1, Sandra Goebbels2,6, Martin Begemann1,2,7, Ulrike C Gerwig6, Sönke Langner8, Hauke B Werner6, Sarah Kittel-Schneider5, Georg Homuth9, Christos Davatzikos4, Henry Völzke10, Brian L West11, Andreas Reif5, Hans Jörgen Grabe3, Susann Boretius2,12, Hannelore Ehrenreich1,2, Klaus-Armin Nave2,6.
Abstract
The underlying cellular mechanisms of catatonia, an executive "psychomotor" syndrome that is observed across neuropsychiatric diseases, have remained obscure. In humans and mice, reduced expression of the structural myelin protein CNP is associated with catatonic signs in an age-dependent manner, pointing to the involvement of myelin-producing oligodendrocytes. Here, we showed that the underlying cause of catatonic signs is the low-grade inflammation of white matter tracts, which marks a final common pathway in Cnp-deficient and other mutant mice with minor myelin abnormalities. The inhibitor of CSF1 receptor kinase signaling PLX5622 depleted microglia and alleviated the catatonic symptoms of Cnp mutants. Thus, microglia and low-grade inflammation of myelinated tracts emerged as the trigger of a previously unexplained mental condition. We observed a very high (25%) prevalence of individuals with catatonic signs in a deeply phenotyped schizophrenia sample (n = 1095). Additionally, we found the loss-of-function allele of a myelin-specific gene (CNP rs2070106-AA) associated with catatonia in 2 independent schizophrenia cohorts and also associated with white matter hyperintensities in a general population sample. Since the catatonic syndrome is likely a surrogate marker for other executive function defects, we suggest that microglia-directed therapies may be considered in psychiatric disorders associated with myelin abnormalities.Entities:
Keywords: Demyelinating disorders; Inflammation; Mouse models; Neuroscience; Schizophrenia
Mesh:
Substances:
Year: 2017 PMID: 29252214 PMCID: PMC5785265 DOI: 10.1172/JCI97032
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808